Trial Profile
A Randomised Phase II study of veliparib and radiotherapy with adjuvant temozolomide and veliparib versus standard radiotherapy and temozolomide followed by temozolomide in patients with newly diagnosed glioblastoma with unmethylated O (6)-methylguanine-DNA methyltransferase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms VERTU
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Primary endpoint (Progression-free survival rate at 6 months (PFS-6) by neuro-radiological review using Response Assessment in Neuro-Oncology (RANO) criteria) has not been met according to the results published in the Neuro-Oncology
- 01 Oct 2021 Results assessing the preliminary efficacy and safety of this sequential veliparib-containing regimen for participants with newly diagnosed MGMT-unmethylated glioblastoma published in the Neuro-Oncology